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       Chronic heart failure (HF) is characterized 
by sympathetic overactivity and enhanced 
circulating catecholamines (CAs), which 
significantly increase HF morbidity and 
mortality.  We recently reported that adrenal G 
protein-coupled receptor kinase 2 (GRK2) is 
up-regulated in chronic HF, leading to 
enhanced CA release via 
desensitization/downregulation of the 
chromaffin cell α2-adrenergic receptors 
(α2ARs) that normally inhibit CA secretion.  
We also showed that adrenal GRK2 inhibition 
decreases circulating CAs and improves 
cardiac inotropic reserve and function.  Herein, 
we hypothesized that adrenal-targeted GRK2 
gene deletion before the onset of HF might be 
beneficial by reducing sympathetic activation.  
To specifically delete GRK2 in the chromaffin 
cells of the adrenal gland, we crossed 
PNMTCre mice, expressing Cre recombinase 
under the chromaffin cell-specific 
phenylethanolamine N-methyl transferase 
(PNMT) gene promoter, with floxedGRK2 
mice.  After confirming a significant (~50 %) 
reduction of adrenal GRK2 mRNA and protein 
levels, the PNMT-driven GRK2 knockout (KO) 
offspring underwent myocardial infarction 
(MI) to induce HF. At 4 weeks post-MI, plasma 
levels of both norepinephrine and epinephrine 
were reduced in PNMT-driven GRK2 KO, 
compared to control mice, suggesting markedly 
reduced post-MI sympathetic activation.  This 
translated in PNMT-driven GRK2 KO mice 
into improved cardiac function and dimensions 
as well as amelioration of abnormal cardiac 
βAR signaling at 4 weeks post-MI. Thus, 
adrenal-targeted GRK2 gene knockout 
decreases circulating CAs, leading to improved 
cardiac function and β-adrenergic reserve in 
post-MI HF.  GRK2 inhibition in the adrenal 
gland might represent a novel sympatholytic 
strategy that can aid in blocking HF 
progression. 
 
       Despite recent advances in prevention and 
management of heart disease, death due to chronic 
heart failure (HF) continues to rise and new and 
innovative treatments are needed (1,2). A salient 
feature of HF is elevated sympathetic nervous 
system (SNS) activity and outflow, reflected by 
increased circulating catecholamines (CAs).  
Initially an adaptive process to compensate for 
decreased function following cardiac injury 
through stimulation of β-adrenergic receptors 
(βARs), SNS activation becomes maladaptive, 
contributing significantly to disease morbidity and 
mortality (3-5). Levels of norepinephrine (NE) are 
associated with worsened prognosis in HF (6). 
Epinephrine (Epi) and, to a lesser extent, NE 
secretion from the adrenal medulla provides 
essentially all circulating CAs and is a 
fundamental component of SNS outflow (7,8). 
Chronic CA elevation in the heart causes 
significant dysregulation of βARs that include a 
myriad of molecular abnormalities (9). Included is 
the up-regulation of G protein-coupled receptor 
kinase 2 (GRK2 or βARK1), which contributes 
significantly to βAR and ventricular dysfunction 
(4,5). 
       α2ARs play a crucial role in autocrine 
feedback inhibition of CA release from cardiac 
sympathetic nerve terminals and from the adrenal 
medulla. In the latter tissue, they reside in 
membranes of chromaffin cells, which are 
responsible for adrenal CA production (10,11).  
The importance of α2AR-mediated SNS activity 
regulation in cardiac disease has been well 
documented in a variety of knockout (KO) mouse 
models (12-14), and in HF patients (15,16). We 
recently reported that, in addition to myocardium, 
GRK2 is up-regulated in the adrenal gland in 
animal models of HF, leading to enhanced CA 
release via desensitization/downregulation of the 
chromaffin cell α2ARs (17). We also showed that 
adrenal GRK2 inhibition via adenoviral-mediated 
in vivo gene therapy using the βARKct (a GRK2 
inhibitory peptide) (18) acutely decreases 
circulating CAs and improves cardiac inotropic 
reserve and function (17). 
In the present study, we posited that 
adrenal-targeted GRK2 gene deletion, before the 
onset of HF, might be beneficial by reducing 
sympathetic activation.  To specifically delete 
GRK2 in the chromaffin cells of the adrenal gland, 
we took advantage of the Cre/loxP technology (19) 
and crossed PNMTCre mice, expressing Cre 
recombinase under the gene promoter of the 
chromaffin cell-specific enzyme 
phenylethanolamine N-methyl transferase 
(PNMT) (20), with floxed GRK2+/+ mice (21). In 
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order to induce HF, resultant mice homozygous 
for the floxed allele (i.e. PNMTCre+/-
/floxedGRK2+/+) and control mice with 
endogenous GRK2 expression underwent 
myocardial infarction (MI) and were studied at 4 
weeks post-MI.  Our data demonstrate that 
reduction of circulating CAs via adrenal-targeted 
GRK2 gene deletion can improve cardiac function 
and βAR signaling post-MI and this sympatholysis 
in beneficial in HF.  
 
      Experimental Prodecures 
 
Mouse generation, PCR screening and real-time 
PCR- Screening for the presence of the PNMT-
Cre transgene was done in genomic tail DNA from 
transgenic mice by PCR using a specific primer 
mix, as described (20). Real-time RT-PCR was 
carried out as described (17). 
Western blotting- Western blotting was performed 
in protein extracts of whole adrenal glands and 
hearts using appropriate specific antibodies, as 
described (17).  
Surgical MI- All animal procedures and 
experiments were performed in accordance with 
the guidelines of the Institutional Animal Care and 
Use Committee of Thomas Jefferson University. 
MI was induced by high ligation of the left 
anterior descending coronary artery, as described 
previously (22). 
Plasma and in vitro CA measurements- Plasma 
norepinephrine and epinephrine were determined 
with the BI-CAT EIA kit from ALPCO 
Diagnostics (Windham, NH), as described (17).  
Echocardiographic and hemodynamic 
measurements- Two-dimensional guided M-mode 
and Doppler echocardiography, and closed chest 
cardiac catheterization were performed in mice as 
described (17,22).  
Chromaffin cell culture and in vitro CA secretion 
assays- Chromaffin cells were isolated from 
adrenal glands excised from the mice and cultured 
as described previously (17). The purity of 
cultured chromaffin cells was assessed 
morphologically and by immunofluorescence 
and/or immunoblotting for endogenous expression 
of tyrosine hydroxylase; purity was over 90% in 
all experiments. 
α2AR density measurements- Plasma membranes 
from excised adrenal glands were prepared as 
described (17), and saturation binding was 
performed using the α2AR-specific antagonist 
[3H]-rauwolscine. Data were analyzed by 
nonlinear regression analysis using GraphPad 
Prism (GraphPad Software). 
Cardiac βAR density and cAMP measurements-  
βAR density was measured in isolated cardiac 
plasma membranes using 125I-CYP 
(Iodocyanopindolol), as described (23). Cardiac 
cAMP levels were measured with the BIOMOL 
Cyclic AMP PLUS EIA kit (Biomol, Plymouth 
Meeting, PA), as described (23).  
Statistical analysis- Data are summarized as 
mean±SEM. Comparisons were made using t tests 
or ANOVA as appropriate. A Bonferroni 
correction was applied to the probability values 
whenever multiple comparisons arose. Values of 
P<0.05 were considered significant.  
 
RESULTS 
 
     Generation of PNMT-driven GRK2 KO mice. 
PNMT-driven GRK2 KO mice were generated by 
crossing the PNMT-Cre and the floxed GRK2+/+ 
mouse lines and breeding the offspring to floxed 
allele homozygosity.  All the mice used in the 
present study were heterozygous for the PNMT-
Cre allele and homozygous for the floxedGRK2 
allele (PNMTCre+/-/floxGRK2+/+).  PCR screening 
in tail genomic DNA confirmed the presence of 
the PNMT-Cre allele in the offspring (Fig. 1A).  
GRK2 gene deletion induced by adrenal 
chromaffin cell expression of Cre recombinase led 
to a significant (53.1±0.5 %) reduction of total 
adrenal GRK2 mRNA levels in the PNMT-driven 
GRK2 KO mice compared to control wild-type 
(WT) floxed GRK2+/+ mice (Fig. 1B).  Of note, 
total adrenal mRNA levels of GRK3 and GRK5, 
the two most important of the other ubiquitously 
expressed GRKs (4), were unchanged (data not 
shown), confirming the specificity of this genetic 
deletion approach as well as the fact that it did not 
cause any compensatory changes in the levels of 
other adrenal GRKs when GRK2 was lost. 
Importantly, western blotting of total adrenal 
protein extracts from PNMT-driven GRK2 KO 
and WT mice confirmed a significant loss (~50%) 
of GRK2 protein consistent with the loss of GRK2 
gene expression in only the chromaffin cells (Fig. 
2A&B).  
 4  
      Adrenal phenotypic characterization of 
PNMT-driven GRK2 KO mice. After confirming 
the success of GRK2 gene deletion in CA-
producing chromaffin cells, we investigated the 
adrenal phenotype of PNMT-driven GRK2 KO 
mice. First, PNMT-driven GRK2 KO mice are 
viable, reproduce normally and present without 
any significant abnormalities. Previously, we have 
found that in HF, adrenal GRK2 up-regulation is 
accompanied by significant adrenal hypertrophy 
and elevated CA biosynthetic activity, as reflected 
by tyrosine hydroxylase (TH) upregulation, the 
enzyme that catalyzes the rate limiting step in CA 
biosynthesis (7,8). Therefore, we measured 
adrenal size and TH expression in adult (two-
month-old) PNMT-driven GRK2 KO and WT 
mice. We found that chromaffin cell GRK2 
deletion leads to a significant decrease of adrenal 
size (Fig. 2C & Table 1). In addition, adrenal TH 
is down-regulated to a similar extent (~50 % at the 
protein level) in 2-month-old PNMT-driven GRK2 
KO mice compared to age-matched control WT 
mice (Fig. 2A&B). A full outline of the overt 
phenotypic features of these mice can be found in 
Table 1. Taken together, these results suggest that 
chromaffin cell GRK2 deletion leads to 
attenuation of adrenal growth and CA biosynthetic 
activity during development. 
       Adrenal α2AR signaling status in PNMT-
driven GRK2 KO mice. We also investigated the 
impact of chromaffin cell-targeted GRK2 deletion 
on the signaling status of the sympatho-inhibitory 
α2ARs, which regulate CA secretion from these 
cells (8,10). Saturation ligand binding in plasma 
membranes from the adrenal glands of PNMT-
driven GRK2 KO mice revealed a significant 
upregulation of α2ARs compared to age-matched 
control WT mice (Fig. 3A). Consistent with this, 
in vitro CA secretion assays in chromaffin cells 
isolated and cultured from the adrenals of these 
mice showed that, in cells derived from PNMT-
driven GRK2 KO`s, the α2AR agonist UK14304 is 
capable of producing a larger (maximal) inhibition 
of nicotine-induced CA secretion compared to WT 
mouse-derived chromaffin cells (Fig. 3B). Taken 
together, these experiments confirm that the 
absence of GRK2 from the chromaffin cells of 
PNMT-driven GRK2 KO mice leads to increases 
in both functional α2AR number and α2AR 
signaling/function in these cells, thus providing 
proof of concept for the generation of these mice. 
       Levels of post-MI HF sympathetic activation 
in PNMT-driven GRK2 KO mice. We have 
previously reported that adrenal GRK2 is an 
important regulator of adrenal CA secretion and 
hence of circulating CA levels, both in normal 
animals and in HF (17,24).  Thus, we investigated 
the impact of GRK2 loss in chromaffin cells on 
circulating plasma CA levels.  We measured CA 
levels in PNMT-driven GRK2 KO and WT mice 
under basal conditions (using Sham-operated 
mice) and also 4 weeks after surgically induced 
MI. Interestingly, plasma levels of both NE and 
Epi were similar between Sham WT and PNMT-
driven GRK2 KO mice (Fig. 4). This is consistent 
with the reported finding that mono-allelic Cre 
insertion into the PNMT locus does not result in 
changes of the levels of either catecholamine (20). 
Indeed, plasma levels of both NE and Epi were 
similar between the control WT floxedGRK2+/+ 
used in this study and PNMT-Cre+/- mice (data not 
shown).  Following MI (4 weeks), we found that 
overall survival post-MI was similar in both 
groups of mice (data not shown), however, we 
found a significant difference in plasma CAs 4 
weeks post-MI as both NE and Epi levels were 
significantly lower in PNMT-driven GRK2 KO 
mice compared to WT mice (Fig. 4).  This result 
strongly suggests that PNMT-driven GRK2 
deletion results in significant attenuation of post-
MI sympathetic activation/increased outflow.   
        In vivo cardiac function 4 weeks after MI. We 
next investigated the impact of reduced post-MI 
circulating CA levels in PNMT-driven GRK2 KO 
mice on the development of cardiac dysfunction.  
As shown in Fig. 5A, cardiac ejection fraction (EF 
%) is significantly increased in KO mice 
compared to WT mice (>10% improvement) at 4 
weeks post-MI whereas both groups of sham-
operated animals exhibited similar EF % values.  
Further, post-MI left ventricular (LV) remodeling 
was slightly but significantly attenuated in KO 
mice compared to WT mice as indicated by the 
reduction of LV end-diastolic diameter (LVEDD) 
(Fig. 5B). Additionally, in vivo cardiac 
catheterization of these mice at 4 weeks post-MI 
revealed markedly decreased basal and 
isoproterenol-induced cardiac contractility in both 
groups compared to sham animals (Fig. 5C). 
Importantly, although basal +dP/dtmax responses 
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were similar between PNMT-driven GRK2 KO 
and WT mice post-MI, PNMT-driven GRK2 KO 
mice had significantly improved responsiveness to 
isoproterenol compared to post-MI WT mice (Fig. 
5C).   
        Of note, LV infarct size was similar between 
the two groups at 24 hrs post-MI (Fig. 6), and also 
at 4 weeks post-MI (data not shown), indicating 
that this improvement in cardiac function observed 
in PNMT-driven GRK2 KO`s at 4 weeks post-MI 
was not due to differences in initial myocardial 
damage caused by the coronary artery ligation or 
in viable/functional myocardial mass between the 
two groups. Table 2 provides a complete outline of 
the in vivo echocardiographic and hemodynamic 
parameters of the sham and 4-week post-MI HF 
mice within both groups. Taken together, the 
above physiological data suggest that cardiac 
function and β-adrenergic-stimulated inotropic 
reserve at 4 weeks post-MI are significantly 
improved by the reduction in circulating CA levels 
due to the chromaffin cell-targeted GRK2 
deletion.  In other words, there is less cardiac 
dysfunction 4 weeks post-MI when CA levels are 
decreased due to a loss of adrenal GRK2 
expression. 
       Myocardial β-adrenergic signaling status at 4 
weeks post-MI. We also examined whether the 
observed improvement in cardiac function of post-
MI PNMT-driven GRK2 KO mice translated into 
positive alteration of cardiac βAR signaling at the 
molecular level, since lower sympathetic overdrive 
during HF progression could mean less βAR 
desensitization and downregulation. Accordingly, 
hearts from both sham-operated and HF mouse 
lines were excised at 4 weeks post-MI, and total 
βAR density in plasma membranes isolated from 
these hearts was measured. As expected, HF 
caused a marked cardiac βAR down-regulation in 
both mouse lines at 4 weeks post-MI, compared to 
healthy sham animals (Fig. 7A). However, in post-
MI failing KO hearts this βAR down-regulation 
was significantly attenuated compared to control 
WT hearts (Fig. 7A). In addition, we also 
measured total steady-state 3`, 5`-adenosine 
monophosphate (cAMP) levels in these hearts.  
cAMP is a second messenger activated by 
myocardial βARs crucial for their pro-contractile 
signaling (3,4). As shown in Fig. 7B, myocardial 
cAMP levels in HF control WT hearts were 
significantly reduced compared to sham hearts, 
consistent with impaired βAR signaling in HF.  
Cardiac cAMP levels of HF PNMT-driven GRK2 
KO mice however were essentially restored to the 
levels of sham hearts (Fig. 7B), indicating a 
marked amelioration of cardiac βAR signaling in 
adrenal-targeted GRK2-depleted mice at 4 weeks 
post-MI.  It is important to note that the levels of 
cAMP in PNMT-driven GRK2 KO hearts were 
not elevated above sham (non-failing) heart levels 
and that levels appear to be normalized (Fig. 7B).  
         Finally, we measured myocardial GRK2 
levels and found that GRK2 was significantly 
increased in HF control WT hearts, again as 
expected (Fig. 7C&D).  Interestingly, GRK2 
levels in PNMT-driven GRK2 KO hearts, albeit no 
different from WT hearts in sham healthy animals, 
were markedly reduced at 4 weeks post-MI 
compared to WT hearts at the same time-point, to 
even below the levels of sham hearts (Fig. 7C&D), 
suggesting a complete prevention and/or reversal 
of the contractility-suppressive cardiac GRK2 up-
regulation in failing PNMT-driven GRK2 KO 
hearts. Taken together, these results indicate that 
the reduction of catecholaminergic stimulation of 
the failing heart by the adrenal-specific GRK2 
deletion significantly ameliorates myocardial βAR 
number, signaling and function, which probably 
underlies, in turn, the improvement in cardiac 
function. 
         Cardiac remodeling and functional 
biomarkers at 4 weeks post-MI. To further analyze 
morphological and molecular aspects of adverse 
cardiac remodeling, we also assessed mRNA 
expression levels of specific genes known to play 
important roles in HF pathogenesis.  The heart 
weight-to-body weight (HW/BW) ratio was 
significantly increased in control WT mice at 4 
weeks post-MI compared to the sham groups 
consistent with a HF phenotype, while cardiac 
mass was significantly decreased in PNMT-driven 
GRK2 KO mice 4 weeks after MI (Table 2). For 
molecular LV remodeling and hypertrophy status 
characterization, we measured the mRNA levels of 
collagen 1 (Col-1), atrial natriuretic factor (ANF) 
and transforming growth factor-β1 (TGFβ1) in the 
LV of all groups via RT-PCR. Consistent with the 
echocardiographic data presented above (Fig. 5), 
Col-1, ANF and TGFβ1 mRNA levels were 
markedly increased in control WT hearts at 4 
weeks post-MI, as expected, and levels of these 
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detrimental cardiac markers were significantly 
reduced in PNMT-driven GRK2 KO hearts over 
the same post-MI time-period (Fig. 8A-C). These 
results demonstrate that the reduction of cardiac 
sympathetic activation by the adrenal-specific 
GRK2 deletion results in significant attenuation of 
post-MI HF-related remodeling.  Finally, mRNA 
levels of brain natriuretic peptide (BNP), a fetal 
gene marker of cardiac hypertrophy, HF and 
volume overload, were measured.  Levels of BNP 
were again markedly elevated in control WT 
hearts at 4 weeks post-MI as expected, whereas 
KO hearts showed significantly lowered BNP 
expression (Fig. 8D).  This favorable change in 
BNP levels is entirely consistent with the 
echocardiographic and hemodynamic analysis 
results presented above (Fig. 5 and Table 2). Of 
note, the adrenal hypertrophy present in WT mice 
after MI, as expected (17), appears significantly 
attenuated in PNMT-driven GRK2 KO mice at 4 
weeks post-MI, as well (Table 2).  
        
 
DISCUSSION 
 
In previous studies, we documented a 
crucial role for adrenal GRK2 in regulation of 
cardiac sympathetic stimulation, both under 
normal conditions and in the context of chronic 
HF (17,24, and reviewed in 11). In the present 
study, we sought to investigate whether 
suppression of adrenal GRK2 before the onset of 
HF can confer any benefit in progressing post-MI 
HF by reducing cardiac sympathetic burden.  To 
this end, we developed a new transgenic mouse 
model having the GRK2 gene specifically deleted 
in the chromaffin cells of the adrenal medulla 
(PNMT-driven GRK2 KO), by utilizing the well 
established Cre/loxP technology (19), and we 
induced chronic HF by surgical MI in these mice.  
Our findings show that adrenal-restricted GRK2 
deletion indeed leads to a significant reduction of 
circulating CAs in vivo in post-MI HF, thus 
proving the concept of the transgenic animal 
approach employed, and, importantly, this 
resultant reduction of both circulating CAs (NE 
and Epi) appears indeed to impede the 
deterioration of cardiac function and βAR 
signaling which are hallmarks of the post-MI 
chronic HF progression. 
Previously, GRK2 was found, by tightly 
regulating the activity and function of the 
sympatho-inhibitory α2ARs of the adrenal gland 
and of the central SNS, to be a key regulator of the 
CA levels present at the heart at any given time, 
and hence of the levels of cardiac 
catecholaminergic stimulation, which is an 
important factor affecting morbidity and mortality 
in HF (6,9). Moreover, we have shown that 
adrenal GRK2 inhibition via adenoviral-mediated 
in vivo gene therapy acutely decreases circulating 
CAs and improves cardiac inotropic reserve and 
function in rats with already established HF (10 
weeks post-MI) (17). With the data from the 
current study, it is now even clearer that lowered 
GRK2 expression and activity in the adrenal gland 
can have a significant beneficial impact on the 
injured heart by imparting a sympatholytic effect 
on CA secretion from the adrenal medulla. 
Importantly, the PNMT-driven GRK2 KO 
mice appear viable and normal and present no 
gross phenotypic abnormalities. Interestingly, with 
regard to their adrenal phenotype, they appear to 
have significantly reduced CA biosynthetic 
activity, as reflected by the down-regulation of TH 
present in their adrenals. In addition, the size of 
their adrenals is reduced compared to WT animals 
at two months of age (Table 1), and, intriguingly, 
they also display significantly attenuated adrenal 
hypertrophy at 4 weeks post-MI (Table 2). Thus, 
adrenal GRK2 seems to be an important trophic 
factor for the adrenal gland in health, but also a 
major driving force behind adrenal hypertrophy 
and hyperfunctioning in HF. These findings are 
also consistent with the up-regulation of adrenal 
TH and the enhanced adrenal hypertrophy 
observed in HF rats, where adrenal GRK2 is also 
up-regulated, and also with the reduction of 
adrenal TH levels of HF rats observed when 
adrenal GRK2 is inhibited in vivo (17). In 
addition, GRK2 emerges as a critical regulator of 
adrenal CA biosynthetic function in general, with 
its activity driving the organ towards increased 
production of CAs.  The mechanisms for this are 
not clear at the moment.  It could very well be an 
indirect mechanism, i.e. increased GRK2 leads to 
enhanced CA secretion which in turn forces the 
adrenal medulla to produce more CAs to meet the 
growing demand, but GRK2 might also be more 
directly involved in adrenal CA biosynthesis, e.g. 
via regulation of specific biosynthetic enzymes.  In 
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any case, the mechanisms of this relationship of 
GRK2 with CA biosynthetic function in the 
adrenal gland will be of great interest to study and 
will be the focus of future studies. 
Perhaps the most important finding of the 
present study is that adrenal-targeted GRK2 
deletion causes a substantial reduction in 
circulating CAs post-MI, although it does not 
affect CA levels in normal, sham-operated mice.  
This finding confirms that the genetic 
perturbations employed to create this PNMT-
driven GRK2 KO line did not have any non-
specific, non-adrenal GRK2-related effects on 
circulating CAs. More importantly, it also strongly 
suggests that adrenal GRK2 is absolutely crucial 
for the elevation of CA levels in post-MI HF, and 
thus, inhibition/suppression of adrenal GRK2 
activity early on after the occurrence of an MI can 
have a powerful sympatholytic effect, which is 
very beneficial in the post-MI HF setting (9,25). 
Admittedly, the reduction in circulating 
CAs conferred by adrenal-specific GRK2 deletion 
in the present study appears relatively small, 
perhaps smaller than might have been expected, 
bringing circulating CA levels nowhere near the 
normal (sham) values.  However, this can be 
explained by the fact that, in the PNMT-driven 
GRK2 KO model described here, GRK2 is deleted 
only in Epi-producing cells and tissues, not in 
every sympathetic tissue in the body (20). 
Therefore, sympathetic neurons can still produce 
and release NE normally. On the other hand, NE 
can still normally stimulate βARs present in 
central (or other) adrenergic/sympathetic neurons, 
which facilitate NE and/or Epi release (26); thus, 
even Epi might not be substantially reduced by the 
GRK2 deletion in adrenal chromaffin cells.  
Therefore, when all these parameters are taken 
into account, the unchanged (with respect to wild 
type) CA levels in normal (sham) PNMT-driven 
GRK2 KO mice and the relatively small CA level 
reductions in these mice observed post-MI are not 
all that surprising. Nevertheless, even slight 
reductions in the catecholaminergic burden of the 
failing heart can have profound beneficial effects 
on cardiac function and overall clinical status of 
the HF patient (27). In fact, excessive plasma CA 
reduction has been postulated to actually be 
deleterious rather than beneficial in HF patients 
(27,28). Thus, it is absolutely plausible that the 
reductions in circulating CAs we observed in the 
PNMT-driven GRK2 KO mice can significantly 
impact cardiac function and βAR signaling post-
MI in a beneficial manner.   
The final interesting finding of the present 
study is the observed down-regulation of GRK2 in 
the failing hearts of PNMT-driven GRK2 KO 
mice. Since myocardial GRK2 critically regulates 
cardiac βAR signaling and function and hence 
cardiac performance and its up-regulation post-MI 
is a major contributor to the functional worsening 
of the failing heart (3,4,5,23), this finding is 
reflective of the improved cardiac βAR signaling 
and function induced by CA reduction in the HF 
PNMT-driven GRK2 KO mice. However, it 
additionally suggests a close dynamic regulation 
of myocardial GRK2 activity by the levels of 
cardiac catecholaminergic activation (23,29), 
which in turn are tightly regulated by GRK2 
activity in the adrenal glands and in the central 
SNS (11,17). Thus, the findings of the present 
study reinforce the notion that GRK2 is a key 
molecule in fine-tuning cardiac function, both 
basally and after sympathetic stimulation, and in 
particular in circumstances where this function is 
severely compromised, such as in the chronic HF 
setting (11). 
Overall, the present study reports that 
adrenal-targeted GRK2 gene deletion helps halt 
progression of cardiac contractile dysfunction and 
adverse remodeling and restores the abnormalities 
of cardiac βAR signaling in post-MI chronic HF 
by significantly reducing circulating 
catecholamine levels after cardiac injury, which 
are extremely toxic for the failing heart (6,25). Of 
note, the beneficial effects of adrenal-specific 
GRK2 deletion also include down-regulation of 
cardiac GRK2, an important indicator of cardiac 
dysfunction in HF, and are evident even without a 
dramatic reduction in CA levels, which could be 
detrimental for cardiac hemodynamic support of 
the circulation and incompatible with life (27,28).  
Thus, reduction of sympathetic activity/outflow 
via adrenal GRK2 inhibition as early as possible in 
the course of post-MI HF progression emerges as 
an attractive therapeutic strategy in the 
management of LV dysfunction. 
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FIGURE LEGENDS 
 
Fig. 1. (A) PCR screening in tail genomic DNA from PNMTCre/FloxedGRK2 (PNMTCre/Flox) or 
control FloxedGRK2 (Flox) mice for confirmation of PNMT locus insertion of the Cre transgene.  An 
additional lane run without DNA (H2O), thus serving as negative control for the assay is also shown.  (B) 
Real time PCR in total adrenal mRNA isolated from two-month-old PNMT-driven GRK2 KO or control 
FloxedGRK2 (WT) mice for determination of total adrenal GRK2 mRNA levels. *, p<0.05, n=6 
mice/litter. 
 
Fig. 2. (A) Representative western blots in total adrenal protein extracts from 2-month-old PNMT-driven 
GRK2 KO or control FloxedGRK2 (WT) mice for total adrenal GRK2 or Tyrosine Hydroxylase (TH) 
protein levels.  Blots for the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
as loading control, are also shown. (B) Densitometric quantitation of the 4 independent experiments done 
in (A) using GAPDH levels as normalization control.  *, p<0.05, vs. WT, n=4 independent experiments 
performed in extracts from 6 adrenals pooled from 3 mice/litter each. (C) Adrenal weight-to-body 
weight (AW/BW) ratios of these mice (see also Table 2). *, p=0.023, n=10 mice/litter. 
 
Fig. 3: (A) Plasma membrane α2AR density in the adrenal glands of 2-month-old PNMT-driven GRK2 
KO or control FloxedGRK2 (WT) mice. Non-specific binding was determined in the presence of 0.4 mM 
phentolamine. *, p<0.05, vs. WT, n=3 independent experiments, performed with 8 adrenals pooled from 4 
mice/litter each. Data are expressed as mean ± s.e.m. (B) In vitro catecholamine secretion from 
chromaffin cells isolated from these mice after nicotine treatment, following pretreatment with vehicle 
(Nicotine) or with 10 µM UK14304 (UK14304 + Nicotine). UK14304 pre-treatment alone had no effect 
(data not shown). *, p<0.05, vs. WT/Nicotine, **, p<0.05, vs. WT/UK14304 + Nicotine, n=3 independent 
experiments, performed with cells isolated from 10 adrenals pooled from 5 mice/litter each.  
 
Fig. 4. Plasma circulating norepinephrine and epinephrine levels in normal, sham-operated (Sham) or in 
4-week post-MI HF (MI) PNMT-driven GRK2 KO (PNMT GRK2 KO) and control FloxedGRK2 (WT) 
mice. *, p<0.05, vs. Sham-either genotype, **, p<0.05, vs. WT MI, n=6 mice/group. 
 
Fig. 5. (A) Ejection fraction (EF %) of sham-operated (sham) or of 4-week post-MI HF (MI) PNMT-
driven GRK2 KO (PNMT GRK2 KO) and control FloxedGRK2 (WT) mice.  *, p=0.005, vs. WT MI, 
n=10 mice/group. (B) Left Ventricular End Diastolic Diameter (LVEDD) of these mice.  *, p<0.05, vs. 
sham, **, p<0.05, vs. WT MI, n=10 mice/group. (C) Basal and maximal dose of isoproterenol (Max. Iso)-
stimulated +dP/dtmax responses of these mice.  *, p<0.05, vs. sham, **, p<0.05, vs. Max. Iso/MI WT, n=7 
mice/group. 
 
Fig. 6: Infarct size in PNMT-driven GRK2 KO (KO) and WT mice at 24 hrs post-MI. Sham hearts are 
also shown as negative controls. (A) Representative triphenyltetrazolium chloride (TTC)–stained cardiac 
cross-sections. (B) Average left ventricular (LV) infarct size (n=5 for each group). No significant 
difference between the MI groups was observed (p=0.05).  
 
Fig. 7. (A) βAR density in cardiac plasma membranes of sham-operated (sham) or of 4-week post-MI HF 
(MI) PNMT-driven GRK2 KO (KO) and control WT mice.  *, p<0.01, vs. either Sham, **, p<0.05 vs. MI 
WT, n=6 hearts/group.  (B) Steady-state total cAMP levels in cardiac homogenates purified from hearts 
of these mice.  *, p<0.05 vs. all other groups, n=6 hearts/group.  (C) Representative western blots in total 
cardiac protein extracts from these mice for cardiac GRK2 protein levels.  Blots for the housekeeping 
protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as loading control, are also shown.  (D) 
Densitometric quantitation of the blots done in (C), using GAPDH levels as normalization control. *, 
p<0.05, vs. respective Sham, n=6 hearts/group. 
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Fig. 8. Heart mRNA levels of (A) collagen I (Col1);  (B) atrial natriuretic factor (ANF);  (C) transforming 
growth factor β1 (TGFβ1);  (D) brain natriuretic peptide (BNP) in all experimental groups at 4 weeks 
post-MI.  All values were standardized to amplified 28S rRNA.  Data are presented as mean ± SEM and 
plotted as fold of sham WT values. *, p<0.05, vs. MI WT, n=6 hearts/group. 
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Table 1: Basic phenotypic characteristics of 2-month-old male WT and PNMT-driven 
GRK2 KO mice 
 
                                                                                   WT                        PNMT-driven GRK2 KO 
                 Heart weight                                               140+ 5.0 mg                               136+ 4.0 mg 
                 Adrenal weight                                            2.5+ 0.2 mg                                1.6+ 0.3 mg* 
                 Body weight                                               27.8+ 0.9 g                                26.9+ 1.0 g 
                 Liver weight                                                 2.1+ 0.2g                                   2.2+ 0.2 g 
                 Lung weight                                                175+ 13 mg                               181+ 11 mg 
                 Kidney weight                                             630+ 71 mg                               645+ 75 mg 
 
*, p<0.05 vs. WT, n=10. Note: The basic cardiac functional parameters of these mice are 
presented in Table 2 (see columns for Sham/WT and Sham/KO of Table 2).  
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Table 2: Cardiac functional parameters in sham and post-MI WT and PNMT-driven 
GRK2 KO mice 
 
                               Sham/WT            Sham/KO                         post-MI/WT                   post-MI/KO  
LVIDs (mm)  2.34±0.08             2.32±0.11                   4.39±0.12#                       3.31±0.21#,* 
LVIDd (mm)  3.88±0.15  3.96±0.08   4.99±0.12#             4.69±0.06#,* 
FS (%)  38.52±0.14     39.25±2.39               13.77±1.13#             20.11±0.35#,* 
EF (%)  69.6±1.97            70.12±3.02   30.90±1.65#             41.17±0.97#,* 
PWTd (mm)  0.95±0.05   1.00±0.02    1.28±0.01#              1.11±0.04#,* 
 
Basal Hemodynamic Measurements 
HR (min–1)           468.2±2.9    477.6±11.5                  457.6±12.5                                 456.3±8.7 
+dP/dtmax               5,430±29               5,432±49                            4,552±63#               4,448±75# 
(mmHg/s)        
–dP/dtmin              -5,159±206            -5,041±101                         -4,379±104#              -4,298±57# 
(mmHg/s)                                
LVESP (mmHg)    98.4±1.1               98.8±1.86     83.43±4.4#               86.14±1.8# 
LVEDP (mmHg)    3.8±0.4      4.0±0.4     11.2±0.8#               10.7±1.4# 
 
Hemodynamic Measurements after maximal Isoproterenol (333 ng/kg BW) 
HR (min–1)    576±17.2      581±7.2                            578±13.3                         582±7.1 
+dP/dtmax    9,717±740    10,451±230     6,689±328#               8,273±489#,* 
(mmHg/s) 
–dP/dtmin                        -8,456±438    -8,380±255                  -6,557±392#              -6,647±318# 
(mmHg/s) 
LVESP (mmHg)      101±2.3       101±1.8         86±3.1#                  89±3.4# 
LVEDP (mmHg)           4.8±1.4       4.6±0.6        12.4±0.9#                12.25±0.5# 
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Phenotypic data:  
HW/BW (mg/g)       5.03±0.18       5.06±0.13          9.8±0.32#                  8.2±0.09#,*   
AW/BW (mg/g)         0.09±0.01       0.06±0.01+          0.38±0.06#                  0.19±0.03#,*    
 
Echocardiographic and hemodynamic analysis data from 3-month-old sham-operated (Sham) or 
post-MI WT and PNMT-driven GRK2 KO mice on day 28 post-MI. +dP/dtmax, maximal first 
derivative of LV pressure rise; –dP/dtmin, minimal first derivative of LV pressure fall; HR, heart 
rate; LVESP, LV end systolic pressure; LVEDP, LV end diastolic pressure; LVIDd, LV inner 
diameter during diastole; LVIDs, LV inner diameter during systole; FS, fractional shortening; 
EF, ejection fraction; PWTd, posterior wall thickness in diastole; HW/BW: Heart weight-to-body 
weight ratio; AW/BW: Adrenal weight-to-body weight ratio; LV: Left ventricular;  #, p<0.05 vs. 
either sham line, *, p<0.05 vs. post-MI/WT, and +, p<0.05 vs. Sham/WT, n=10 mice/group for 
echo, HW/BW and AW/BW measurements, n=7 mice/group for hemodynamic measurements. 
ANOVA with Bonferroni test were performed among all groups. Data are presented as mean ± 
SEM.   
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